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Cervical cancer is one of the leading female cancers especially in developing 
countries and a common cause of death among middle-aged women. The main role 
of Human Papillomavirus (HPV) in both cervical cancer and pre-invasive lesions 
of the cervix has been proven in studies. Reducing the incidence of the disease can 
be achieved by the regular cervical screening of women and vaccination of appro-
priate age groups. The disease can be better controlled by better elucidating the 
details of HPV carcinogenesis, the interaction between the host and the virus, and 
determinants of the systemic and cellular immune response to the viral infection. 
HPV causes oropharyngeal and anogenital diseases in both men and women and 
is usually sexually transmitted. Most infections are transient and could be cleared 
spontaneously by the host immune system. After the first encounter with HPV 
infection, it takes years to progress to cervical cancer, which gives clinicians a long 
period to follow these patients in terms of precancerous lesions and to investigate 
the pathogenesis of the disease. HPV plays a major role in the development of cervi-
cal cancer, but histological types have different relationships with HPV genotypes. 
HPV can remain latent for a long time and the most important thing determining 
the persistence is the type of HPV. HPV vaccination provides a direct benefit to both 
men and women by providing safe protection against cancers that may result from 
persistent HPV infection.
Keywords: cervical cancer, human papillomavirus, casualty, etiology, screening, 
vaccine
1. Introduction
Worldwide, cervical cancer is the fourth most common cancer among females 
and the third most common female genital tract cancer. 570,000 cases of invasive 
cervical carcinoma were diagnosed and 311,000 cervical cancer deaths occurred 
in 2018 [1, 2]. In low-income countries that do not have access to cervical cancer 
screening and prevention programs, cervical cancer continues to be a major cause 
of cancer diseases and deaths. The prevalence of cervical cancer and precancerous 
lesions depends on how effectively cancer screening programs and HPV vaccines 
are used in populations. The causal relationship between HPV and cervical can-
cer has been well documented [3–6] and HPV can be detected in 99.7 percent of 
cervical cancers [7]. Studies have consistently shown strong geographical cor-
relations between HPV-DNA prevalence and cervical cancer incidence [6]. The 
worldwide spot prevalence of HPV is about 10 percent detected in a meta-analysis 
of studies involving more than 150,000 images with normal cervical cytology [8]. 
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Africa is the most prevalent place of HPV infection in the world, where HPV is 
detected in 22% of African women. The most common types worldwide are HPV 
types 16 and 18, however, there appears to be geographic variation in the distribu-
tion of HPV genotypes.
HPV causes oropharyngeal and anogenital diseases in both men and women and 
is usually sexually transmitted. HPV infections are considered the most common 
sexually transmitted disease in sexually active individuals. It is estimated that at 
least 80% of sexually active individuals have been exposed to HPV once in their 
lifetime [9].
The most common histological type of cervical cancer is squamous cell carci-
noma (SCC) (70%). Although the incidence of invasive cervical adenocarcinoma 
and its variants has gradually increased in the last few years; this type of neoplasia 
accounts for approximately 25% of all invasive cervical cancers diagnosed today. 
Other rare variants also constitute 3–5% of cervical cancer. HPV plays a major role 
in the development of cervical cancer, but histological types have different relation-
ships with HPV genotypes. Available data state that HPV 18 accounts for 15% of 
SCCs and about 50% of adenocarcinomas [10]. The highest prevalence of HPV 
infection typically occurs within the first decade after sexual intercourse, typically 
between the ages of 15 and 25 in most western countries. Many sexually active 
young women have sequential infections with different types of oncogenic HPV. 
These infections are usually detected temporarily, but often reversible cytological 
changes occur. HPV spreads from the skin to the skin surface, and cutaneous HPV 
infections are common in the general population. Person-to-person transitions are 
typically asymptomatic [11]. Therefore, unprotected penetrative sexual intercourse 
(both vaginal and anal) or close physical contact from skin to skin is the most 
important factor for HPV infection [12]. Other risk factors are the number of part-
ners [13, 14], new sexual partners [14], high-risk sexual partner, previous sexually 
transmitted disease, young age, not being married, non-Hispanic black, being the 
highest school graduate, poverty, low-income, first coitus at younger than 18 years 
old [8], primary or secondary immunodeficiency conditions. Spread from other 
HPV-infected genital organs, such as post-toilet wiping from front to back, may also 
play a role in the transmission of other types of contact [14, 15]. Penetrating vaginal 
and anal intercourse is not required for passage, but the prevalence of infection is 
much lower in virgins. Female-to-male transmission may occur at a higher rate than 
male-to-female transmission [16]. Regular condom use reduces the risk of HPV 
infection [17]. However, condoms do not completely prevent the transmission of 
HPV because the virus is spread through skin-to-skin contact.
HPV usually makes its first peak at an early age in unvaccinated sexually active 
women. Humoral and cellular immunity is provided with natural immunity 
partially [18, 19]. The presence of anti-HPV antibodies in patients with previous 
HPV type 16 infection has been associated with a lower risk of infection later, 
and it is thought that protective immunity is formed [18, 20–22]. However, it is 
not known how long and how much this protection lasts. It has been documented 
that some individuals with HPV infection did not develop antibodies [22, 23]. The 
second peak is in the postmenopausal period [24, 25]. This may be due to weakened 
cellular immunity or persistence or reactivation of a previously acquired infection. 
Reactivation may be the main source of newly detected HPV infection in HIV-
positive women [26]. The oncogenic activity of HPV increases in the postmeno-
pausal period. New HPV infection in older women does not usually progress to 
preinvasive disease or cancer.
HPV can remain latent for a long time and the most important thing deter-
mining the persistence is the type of HPV. HPV infection is best documented by 
molecular tests. PCR and in situ hybridization are mostly used in HPV typing. 
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With cytological examinations, only 30% of the patients represent the presence of a 
cytological disorder caused by HPV. A high-risk HPV type is responsible for 95% of 
pre-invasive lesions of the cervix and cervical cancer.
HPV has more than 200 types and can be divided into subgroups as mucous 
or cutaneous types according to their tissue tropism. Typing depends on DNA 
sequence and homology. Each type was separately identified as having less than 
90% DNA base pair homology with another HPV strain. In addition to HPV 
genotypes, HPV intratypic variants also have epidemiological and oncogenic value 
in cervical cancer [27]. Different HPV types tend to infect different parts of the 
human body and are therefore associated with different diseases. The most common 
types of HPV associated with certain lesions vary according to the geography and 
demography of the population studied, but generally HPV types 6 and 11 cause 
condyloma acuminata, while type 16,18,31,52 cause intraepithelial neoplasms of the 
cervix [26, 28]. Over 40 HPV types showing tropism to the anogenital epithelium 
enter the epithelium of the penis, scrotum, perineum, anal canal, perianal area, 
vaginal introitus, vulva, and cervix. Approximately 15 HPV types are known as 
high risk, carcinogenic, or cancer-related [8]. High risk HPV types; 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, and 68 low-risk HPV types; 6, 11, 40, 42, 43, 44, 53, 54, 
61, 72, 73, and 8. Among these, the most common HPV type in cervical cancer is 
type 16, and the intraepithelial neoplasia it causes is the type most likely to progress 
to cancer [3]. The reason of low-risk HPV types not causing cancer is that they 
cannot integrate into the host cell’s chromosome. The E6 and E7 genes of such HPV 
viruses bind weakly to p53 and pRb. The presence of a cervical transformation site 
is not necessary for oncogenic HPV to infect the female genital tract. Because HPV 
can also cause cancer in the vulva, vagina, and anal region, the epithelium of which 
is mentioned before, squamous keratinized epithelium. HPV 18 causes disease more 
frequently in younger women and recurrence is more than that of HPV 16. In cervi-
cal cancer, the specificity of HPV 18 is higher than that of HPV 16. HPV 16 and 18 
involve the cervix more than other HPV types with low oncogenic potential.
2. Basic virology
The link between genital HPV infections and cervical cancer was first demon-
strated in the early1980s by Harold Zur Hausen, since then, the biology of HPV 
viruses has been extensively studied and has proven well connected with neoplasia.
HPV is an epithelotrophic virus from the Papillomaviridae family, small, 
non-enveloped, encapsulated, 55 nm in diameter, containing double helix 8 kilo-
base circular DNA. Human papillomaviruses are a big family with the systematic 
classification of five genera (α, β, γ, μ, and ν), 48 species, and 206 types [27]. The 
genetic map of HPV-16 is illustrated in Figure 1 [29]. It is coated with 72-surface 
icosahedral protein capsid which contains at least two capsid proteins, L1 and L2. 
HPV genome contains 7900 base pairs. It encodes 8 genes that can encode early and 
late proteins and URR, which control the transcription of late genes without coding 
[30]. Early proteins are associated with viral gene regulation and cell transforma-
tion, while late proteins form the coat of the virus [31, 32]. Specific gene products 
are duplicated at each differentiation level of squamous keratinocyte [33]. At the 
most superficial level, the L1, L2, and E4 genes are duplicated for assembly of the 
viral capsid in which the HPV genome is packaged. After the short-lived superficial 
cells desquamate, infectious HPV virions are released for the next round of infec-
tion. E1,2,5,6 and 7 are expressed in the early period of differentiation of HPV in 
the epithelium, L1 and L2 are expressed in the late period, and E4 is expressed dur-
ing differentiation. E4 is the gene most associated with viral release. E1 and E2 play 
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a critical role in participating in the structure of host DNA. E1 enables the regula-
tion of DNA replication and keeping the virus in episomal form. E2 cooperates with 
E1, ensures viral DNA replication, downregulates E6 and E7 expression [34]. The 
HPV genome remains a stable viral episome in the nucleus of the cell, independent 
of the host cell nucleus. When it causes cervical cancer or pre-invasive diseases of 
the cervix, the HPV genome in the host nucleus integrates into the host cell’s DNA. 
Viral integration into cellular DNA was proposed as a marker of progression to cer-
vical cancer. Integration is rarely seen in the pre-invasive disease. Whether integra-
tion in HSIL stages progresses to cervical cancer is unknown [6]. When E2 is added 
to the DNA structure, it degrades and as a result, E6 and E7 expression is increased 
[35]. In other words, the production of E6 and E7 is mainly under the control of E2. 
E6 and E7 are the major HPV oncoproteins and they work together to immortalize 
epithelial cells [36]. Both E6 and E7 proteins are consistently expressed in cancerous 
tissues. E6 can lead to persistent infections and invasive cancer development with 
its telomerase activity. E6 activates c-myc and increases telomerase activity of the 
catalytic subunit gene (by increasing hTERT transcription) [37]. It has also been 
shown that E6 and E7 antagonize the inhibition of hTERT via BRCA [38].
E6 and E7 proteins of HPV 16 bind more tightly to their targets than other HPV 
types, so HPV 16 becomes more persistent. E6 binds and suppresses p53, which 
blocks the G1 → S step in the cell cycle [39]. Following E6 binding of p53, p53 is 
disrupted in the presence of E6-associated protein [40]. If p53 does not participate, 
DNA damage cannot be repaired. The result is that the global cycle cannot be 
controlled, there is no apoptosis, and chromosomal mutations accumulate because 
there is no DNA repair [41, 42]. E7 binds to the retinoblastoma that regulates 
apoptosis and forces the cell to enter the synthesis step [33]. Retinablostome inac-
tivates the E2F transcription factor that controls DNA synthesis, cyclin function 
Figure 1. 
Genome organization of human papillomavirus. The genetic map of HPV-16.
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and promotes the S phase of the cell cycle. When E7 binds to the Rb protein, E2F is 
released, allowing cyclin A to promote cell turnover [43]. Thus, a cell with unstable 
chromosomes and high-risk HPV can turn into a malignant cell. E6 and E7 are 
essential proteins in immortality transformation. But these two genes are not the 
only ones responsible for cancer development [44]. Progression to neoplasia pos-
sibly involves a genetic change in the pathways that control intracellular or intercel-
lular signaling [45].
E5, on the other hand, disrupts the antigen presentation of MHC-I and MHC-II. 
E5 also activates the EGF pathway [34]. The L1 protein self-assembles in the absence 
of the viral genome to form a virus-like particle (VLP). L1 VLP is the immunogen 
used in HPV vaccines. L2 is the minor capsid protein that mediates HPV infection 
with L1 [46, 47].
3. HPV infection causality in cervical cancer
The role of the HPV virus in cervical cancer development is proven by the dem-
onstration of HPV DNA and viral oncogenes E6 and E7 in cancerous tissues, that 
E6 and E7 gene products have host cell transforming properties, and HPV has been 
shown as a major factor in cervical cancer development in epidemiological studies. 
There are four main steps in the development of cervical cancer [48];
1. One or more oncogenic types of HPV infection of the metaplastic epithelium 
at the cervical transformation zone,
2. Persistence of the HPV infection rather than clearance,
3. Progression of a clone of epithelial cells from persistent viral infection to pre-
cancer (CIN3)
4. Carcinoma invasion through the basement membrane
Initial infection of the basal cell of cervical epithelium occurs as a result of 
microscopic breaks in the epithelium [33]. HPV targets and binds to the heparin 
sulfate proteoglycan receptor located in the basement membrane [49] indicating 
that HPV infection starts from the basement membrane. The replication cycle of 
the virus depends on the maturation of the keratinocyte. Since HPV does not enter 
the bloodstream, it does not cause viremia and inflammation. Therefore, the anti-
gen is not formed against HPV and HPV cannot be detected by blood tests. There 
are also no FDA-approved serological or blood tests to detect HPV infection.
Although HPV infection is common in the population, cervical cancer devel-
ops in a minority of these infected patients. Because most HPV infections are 
temporary and additional factors are required for cancer development. The period 
from the first infection with HPV to the development of cancer is approximately 
15 years. Different subtypes of HPV are detected at different rates in histological 
types of cervical cancer. In squamous cell carcinoma, HPV 16,18,58,33and 45 is 
found in 59%, 13%, 5%,5% and 4% of cases,respectively. In adenocarcinoma, 
HPV 16,18,45,31 and 33 is found in 36%, 37%, 5% percent, 2%,2% of cases, 
respectively [2].
The most expected and most likely outcome in women infected with HPV is 
complete resolution of the infection within 2 years [50, 51]. The least expected 
result is the development of neoplasia [52] and it occurs as a result of persistent 
infection. Currently, there is no effective treatment for HPV persistence [53]. 
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Spontaneous recovery of HPV infection is more likely in young women [6]. Low-
grade lesions caused by HPV can be detected clinically when smears are used for 
screening, but they are usually temporary, however, HPV can become latent [54]. 
It may be reactivated in immunocompromised patients however, it is not known 
which HPV infections become latent and whether recurrent HPV infections carry 
a significant cancer risk. The possibility of pre-cancerous or cancerous lesions 
increases with persistent HPV infections. More than one HPV type can be positive 
in a woman. When women with multiple types of infection were compared with 
women who were positive for only one HPV type, no increased risk was identified. 
This suggests that each HPV type causes disease independently from the other [55].
Although HPV is the most powerful cause for cervical cancer development, 
the presence of HPV alone is not sufficient for cervical cancer, and additional 
factors are required. These factors can be causes such as smoking, endogenous and 
exogenous hormones. HPV is positive in 99% of patients diagnosed with cervical 
cancer. It is thought that an HPV virus type that causes cervical cancer is encoun-
tered around the age of 21 on average [56]. While HPV 16 is responsible for 50% 
of cervical cancer, HPV 18 is responsible for 20% [57]. The remaining cases (19%) 
are caused by HPV 31,33,45,52,58 [58]. While persistent HPV infection progressing 
to CIN3 in 5 years [59], CIN3 progresses to invasive cancer in 30% of patients after 
30 years [60]. Factors such as smoking, multiparity, age at first birth, and the use 
of oral contraceptives facilitate the progression of HPV-infected epithelial cells to 
cancer [61].
Excessive viral load in the lesion does not mean that the lesion will progress to 
cancer, except for HPV 16 [62]. Very high dose viral load may be detected in some 
low-grade lesions, but these lesions may regress over time [8]. Therefore, viral 
load measurement is not useful in the clinic and does not provide any additional 
benefit [63].
4. HPV vaccination
Routine HPV vaccination is recommended for adolescents and young adults in 
many countries. HPV vaccination provides a direct benefit to both men and women 
by providing safe protection against cancers that may result from persistent HPV 
infection. This protective effect has been best demonstrated in cervical cancer, one 
of the most common women’s cancers worldwide. Inactive HPV vaccination can 
prevent HPV infection and its sequelae. Vaccination status does not change recom-
mendations for screening. HPV vaccine provides protection not only from cervical 
caser but also from vulvar, vaginal, oropharyngeal, anal cancers, and anogenital 
warts. There is also evidence of decreased genital warts among men of similar age in 
areas with a high proportion of vaccinated women [64].
The vaccine does not protect against 100 percent of the types known to cause 
cervical cancer since the most extensive vaccine protects against only 9 types of 
HPV. Therefore, women should continue to have cervical screening regardless of 
whether they are vaccinated or not. However, in societies that cannot include the 
HPV vaccine in the routine vaccination program due to economic concerns, it 
is recommended that public health efforts focus primarily on the vaccination of 
young women, the group with the absolute benefit and cost-effectiveness of HPV 
vaccination. However, none of the existing HPV vaccines will cure pre-existing 
vaccine-type HPV infections or related diseases [27], as the vaccine is effective 
if used in primary prevention. Sexually active individuals should be vaccinated 
consistently with recommendations specific to their age. Abnormal Papanicolaou 
test, genital warts, or a history of HPV infection is not a contraindication to HPV 
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vaccination [65]. The HPV vaccine is recommended for these patients as it can still 
protect against infection with HPV vaccine types that have not been encountered yet 
[66, 67]. However, if the individual is previously infected with any HPV type in the 
vaccine, it reduces the protection of the vaccine.
These vaccines contain virus-like particles, but without producing the effect of 
the virus, only activate the body’s immune system, in other words, by initiating the 
production of HPV-type antibodies, enable the woman to become resistant to HPV 
for a long time. Many studies have reported that the prevalence and incidence of 
HPV infection and HPV-related disease decreased following the initiation of HPV 
vaccination [68–71].
The vaccine does not contain virus DNA, it contains capsid particles of the 
virus. The vaccine is produced against the L1 and L2 capsid proteins. L1 VLP 
vaccines strongly stimulate cellular and humoral immunity. There are three types 
of HPV vaccine, bivalent, quadrivalent, and 9-in-1 vaccine, although not all of 
them are available everywhere. Bivalent vaccine is protective against the HPV types 
16 and 18, quadrivalent vaccine and 9-shot to vaccine to,HPV types 16,18,6,11, 
and HPV types 16,18,6,11,31,33,45,52,58 respectively. Although it is not available 
everywhere, it is more advantageous to be vaccinated with a 9-shot vaccine since 
it contains more HPV types that cause cervical cancer. Characteristics of the three 
human papillomaviruses (HPV) vaccines licensed for use in the United States are 
demonstrated in Table 1 [72]. Therapeutic vaccines are under development but not 
clinically available [73].
The best time for HPV vaccination is before an individual has sexual intercourse. 
Clinical trial data on vaccine efficacy in men and women show that vaccination with 
the HPV vaccine is most effective among people not infected with HPV. Although 
it can be applied to individuals of all age groups, routine HPV vaccination is recom-
mended between 11 and 12 years of age [66]. In this age group, the protection of the 
vaccine is almost 100% [74–77]. The resulting titers are generally higher in younger 
people than in older individuals [72]. There is no minimum threshold titer defined 
for protection. The natural history and the determinants of the immune response 
to HPV are still poorly understood [6]. The World Health Organization (WHO) 
Characteristic Bivalent (2vHPV) Quadrivalent (4vHPV) 9-valent (9vHPV)
Brand name Cervarix Gardasil Gardasil 9
VLPs 16, 18 6,11,16,18 6, 11, 16, 18, 31, 33, 45, 
52, 58
Manufacturer GlaxoSmithKline Merck and Co., Inc Merck and Co., Inc
Manufacturing Trichoplusia ni insect 
cell line infected 





















Volume per dose 0.5 ml 0.5 ml 0.5 ml
Administration Intramuscular Intramuscular Intramuscular
Table 1. 
Characteristics of the three human papillomavirus (HPV) vaccines licensed for use in the United States.
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recommends that the primary target of HPV vaccination programs is women 
between the ages of 9 and 14 and that local public health programs only recommend 
that older women be vaccinated if it is cost-effective and does not divert resources 
from vaccinating the primary target population or cervical cancer screening [66]. 
It is recommended to vaccinate men between the ages of 16–26 [72]. The vac-
cine can be administered from the age of 9 years [72], but it is not recommended 
before the age of 9. Compensatory vaccination is recommended for adolescents 
and adults aged 13–26 who have not been vaccinated before or have not completed 
the vaccine series [78] and for males aged 13 through 21 years who have not been 
vaccinated previously or who have not completed the 3-dose series. Males aged 22 
through 26 years may be vaccinated. ACIP recommends vaccination of men who 
have sex with men and immunocompromised persons through age 26 years if not 
vaccinated previously [72]. The decision to vaccinate individuals over the age of 26 
should be made on an individual basis. Because in this age group, the protection of 
the vaccine decreases [79]. While the protection of the vaccine is 81% in individu-
als between the ages of 26–35, it decreases to 75% in individuals between the ages 
of 35–46. The rate of protection is 44% in individuals who have been previously 
infected with HPV [80]. In these cases, the vaccine protects against other types of 
HPV. Persons who are virgin under the age of 26 can have the 9-inoculation vaccine 
if they have had a bivalent or quadrivalent vaccine before. The HPV vaccine is not 
recommended during pregnancy due to limited safety information [72]. Those who 
were vaccinated by mistake during pregnancy do not need termination because no 
relationship has been shown between the HPV vaccine and abortion or poor fetal 
outcomes [81]. Women of reproductive age do not need a pregnancy test before 
vaccination [72]. If conception is achieved between doses, the remaining doses are 
postponed, the remaining doses are completed after pregnancy, and do not start 
over [82]. Vaccine is safe for nursing mothers because inactive vaccines do not affect 
the safety of breastfeeding. There is no need to screen the individual for HPV before 
HPV vaccination [67]. Measurement of post-vaccination antibody titers has no 
clinical use [6] since the protective titer is unknown.
In addition, studies are showing that HPV is present in the smoke that occurs 
during the surgical removal or ablation of HPV-infected tissues and that nasal or 
oropharyngeal HPV infection may develop if this smoke is inhaled by healthcare 
workers [83]. Therefore, it would be beneficial to vaccinate healthcare workers who 
are at risk of such exposure [84]. Studies have shown that the HPV vaccine protects 
women against high-grade lesions of the cervix, vulva, and vagina for 10 years, and 
persistent antibody levels have been found [85–87].
The vaccine is administered in 3 doses [72]. The peak immunity achieved with 
3 doses of vaccination is greater than that of native HPV infection. After 2 years, 
the antibody level drops but is still higher than that of innate immunity [78]. There 
is no evidence of the additional benefit of a booster dose. For individuals under 
15 years of age, 2 doses are sufficient (between 0 and 6–12 months). In this age 
group, if the second dose is administered less than five months after the first dose, 
the dose should be repeated at least 12 weeks after the second dose and at least 
five months after the first dose. It can be applied in 0,1 and 6 months or 0, 2, and 
6 months. The interval between the first and second doses should be a minimum 
of 4 weeks. The interval between the second and third doses should be a minimum 
of 12 weeks. The minimum interval between the first and third doses should be 
5 months. If a dose has been administered at a shorter interval, it should be repeated 
at the minimum recommended interval after the last dose has passed [66, 67, 88]. 
If the dosing schedule is got out of order the remaining doses are made quickly, not 
starting over [67, 72]. Vaccines that can provide the same protection after 1 dose 
are in the development phase. Such a vaccine could be an important breakthrough 
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for low-income countries to prevent disease. If possible, the vaccination should be 
continued with whatever type of vaccine it started. However, if there is a problem 
in accessing the vaccine or if the first vaccine is not known, it can be continued with 
other types of vaccines [72]. Although direct efficacy data on HPV vaccination in 
immunocompromised hosts are lacking, immunocompromised individuals can also 
be vaccinated in the same manner [66]. The HPV vaccine can be safely adminis-
tered in a different anatomical region at the same time with other age-appropriate 
vaccines. Coadministration of HPV vaccine with other vaccines does not affect the 
immune response [83, 89].
Side effects of HPV vaccination are generally limited to mild local reactions 
(regional reaction, systemic malaise, fever) [72] and syncope. Mild injection 
site reactions were the most common side effects in studies [90]. Syncope is not 
specific to the HPV vaccine [90, 91]. None of the side effects already seen are 
characteristic of the HPV vaccine. Following HPV vaccination, a routine waiting 
period of 15 minutes in a sitting or supine position is recommended [67]. Other 
reported side effects include headache, nausea, vomiting, tiredness, dizziness, 
and weakness [43]. The adjuvant aluminum hydroxyphosphate found in the quad-
rivalent and 9-vaccine and the adjuvant aluminum hydroxide + monophosphoryl 
lipid found in the bivalent vaccine is used to increase the immunological response 
of the vaccine. The higher the amount of adjuvant in the vaccine, the more side 
effects it has. For this reason, since the 9-vaccine contains more adjuvant sub-
stances, its side effects occur more [72]. However, the protection of the 9-in-1 
vaccine against HPV 16 and 18 is approximately as much as the quadrivalent 
vaccine [72].
5. Conclusions
Cervical cancer is preventable cancer worldwide with the organized and strict 
compliance of early screening methods, vaccination programs, and changing sexual 
behavior. Aggressive treatments of early or ambiguous cytologic lesions related to 
HPV may result in a decrease in rates of more advanced disease although increases 
in the incidence of cervical adenocarcinomas have been reported in several popula-
tions. Because cervical screening tests are insufficient in detecting adenocarcinoma. 
Since the HPV vaccine is protective against high-risk types, it is beneficial to apply 
it to the recommended age groups.
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